Pancreatic cancer pill daraxonrasib halts tumours in most patients, trial shows

New pancreatic cancer drug stops tumor growth: Study

newsnationnow.com· · 13h
Open

A NewsNation report says a new study finds Daraxonrasib, combined with chemotherapy, substantially shrinks tumors in patients with metastatic pancreatic cancer, one of the hardest cancers to treat. In the study of 60 patients, tumors shrank in more than 60% and became completely undetectable in 8%, while growth stopped in over 90% for an average of over a year before returning. The drug, approved by the FDA in September, works by interfering with signals mutated pancreatic cancer cells depend on to keep dividing. Dr. Wungki Park calls the finding a potentially transformative advance, noting survival already outpaces the historical 8.5 to 11.1 months with conventional chemotherapy, against a backdrop where only 3% of metastatic patients live five years.

Pancreatic cancer pill treatment ‘a big science win’: doctor

ctvnews.ca· · 35h
Open

Dr. Sam Godfrey of Cancer Research UK calls a pancreatic cancer pill treatment in trials "a big science win" and discusses how it works and what it can do.

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

theguardian.com· · 39h
Open

A Guardian article reports on trial results for the pill daraxonrasib, a KRAS inhibitor hailed as the biggest breakthrough in pancreatic cancer treatment in decades: tumours stopped growing in 90% of patients, became undetectable in about 8%, and 76.6% were alive a year on. Doctors caution it is not yet a cure, and Michelle Mitchell calls the results the biggest leap forward in decades while saying more trials are needed before NHS use; longer studies will test whether remission is possible.

Massive hope for pancreatic cancer pill after trial saw tumours vanish

bbc.com· · 2d
Open

A BBC News health report says the experimental pill daraxonrasib, a KRAS inhibitor already approved in the US, produced striking results in early pancreatic cancer trials: tumours stopped growing in 90% of patients and vanished from scans in one in 12. Experts call it the biggest leap forward in decades, though doctors caution longer studies are needed before calling it a cure.

‘Game-changing’ pancreatic cancer drug can make tumours vanish

thetimes.com· · 2d
Open

The Times reports that the pancreatic cancer drug daraxonrasib can make tumours vanish. Trial results show more than three quarters of patients who took it survived past 12 months, compared with 25 per cent on standard chemotherapy, and the paper calls it game-changing.

Sign in with subscription

Free during the beta.

Clear all notifications?

Your bells stay on. Only this list empties.